AI-Powered Insights: Revolutionizing Pharma BD Deals
A panel discussion with:
- Roby Kanichay, Head of Technologies and Externalizations Business Development, Merck
- David Linson, Senior Director-Business Operations and Intelligence, Eli Lilly
- Alexandria Hall, Head of Industry, LifeSciences, Alphasense
- Ivan Griffin, Co-Founder, BenevolentAl
- Steve Lehmann, Director, Venture Operations, Portal Innovations
In the dynamic landscape of pharmaceutical business development (BD), the integration of artificial intelligence (AI) has emerged as a transformative force, reshaping traditional approaches to deal-making. AI-powered insights offer unparalleled capabilities in data analysis, predictive modeling, and decision support, empowering pharmaceutical companies to navigate complex deal structures with precision and agility. This panel discussion delves into the profound impact of AI on pharma BD deals, exploring how advanced analytics and machine learning algorithms are revolutionizing the negotiation process, driving strategic partnerships, and unlocking new avenues for growth and innovation.
- Harnessing data intelligence for strategic decision-making
- Optimizing deal valuation and risk assessment with predictive analytics
- Enhancing due diligence and partner selection processes
- Driving innovation and strategic partnerships through AI collaboration
.png?width=847&height=476&name=AI-Powered%20Insights%20%20Revolutionizing%20Pharma%20BD%20Deals%20(4).png)
